Core Viewpoint - Silver诺医药-B (02591) has seen a significant stock price increase, with a rise of over 30% recently, and currently up 6.11% to 40.3 HKD, with a trading volume of 23.13 million HKD [1] Group 1: Stock Performance - The stock price of Silver诺医药-B increased by over 30% yesterday [1] - As of the latest update, the stock is trading at 40.3 HKD, reflecting a 6.11% increase [1] - The trading volume reached 23.13 million HKD [1] Group 2: Market Inclusion - On November 21, the results of the Hang Seng Index series quarterly review were announced, with Silver诺医药 being included in the Hang Seng Composite Index [1] - The changes from this review will take effect on December 8, 2025 [1] Group 3: Product and Research Insights - According to a report from Shanghai Securities, Silver诺医药's Supraglutide α demonstrates good safety and efficacy in lowering blood sugar and weight [1] - The company shows significant advantages in treating chronic metabolic diseases such as diabetes, obesity, and fatty liver [1] - The listing on the Hong Kong Stock Exchange is expected to facilitate the advancement of the company's research pipeline and commercialization efforts [1]
银诺医药-B再涨超6% 昨日股价飙涨超30% 公司获纳入恒生综指